transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2020-7-5-29-42transmed-583Research ArticleНЕВРОЛОГИЯNEUROLOGYНовые диагностические и прогностические биомаркеры ишемических поражений мозгаNew diagnostic and prognostic biomarkers of the ischemic brain damagehttps://orcid.org/0000-0002-4441-1165АлексееваТ. М.AlekseevaT. M.

Алексеева Татьяна Михайловна, д.м.н., доцент, заведующая кафедрой неврологии и психиатрии

Санкт-Петербург

Alekseeva Tat’yana M., MD, PhD, Dr. Sci., Head of the Department of Neurology and Psychiatry

Saint Petersburg

https://orcid.org/0000-0002-0175-3085ТопузоваМ. П.TopuzovaM. P.

Топузова Мария Петровна, к.м.н., доцент кафедры неврологии и психиатрии

SPIN-код: 1091-9433 WOS Research ID: S-8865-2017 Scopus Author ID: 57201374816 AuthorID (РИНЦ): 922244

ул. Аккуратова, д. 2, Санкт-Петербург, 197341

Topuzova Mariya P., MD, PhD, Associate Professor of the Department of Neurology and Psychiatry

Akkuratova str. 2, Saint Petersburg, 197341

topuzova_mp@almazovcentre.ruhttps://orcid.org/0000-0003-1140-8039ЧайковскаяА. Д.ChaykovskayaA. D.

Чайковская Александра Дмитриевна, аспирант кафедры неврологии и психиатрии

Санкт-Петербург

Chaykovskaya Alexandra D., MD, Postgraduate Student of the Department of Neurology and Psychiatry

Saint Petersburg

https://orcid.org/0000-0003-3637-5405ПанинаЕ. Б.PaninaElena B.

Панина Елена Борисовна, к.м.н., доцент кафедры неврологии и психиатрии

Санкт-Петербург

Panina Elena B., MD, PhD, Associate Professor of the Department of Neurology and Psychiatry

Saint Petersburg

https://orcid.org/0000-0001-8537-3639ВавиловаТ. В.VavilovaT. V.

Вавилова Татьяна Владимировна, д.м.н., профессор, заведующая кафедрой лабораторной медицины и генетики

Санкт-Петербург

Vavilova Tat’yana V., MD, PhD, Dr. Sci., Professor, Head of the Department of Laboratory Medicine and Genetics

Saint Petersburg

https://orcid.org/0000-0003-3553-6537ПоспеловаМ. Л.PospelovaM. L.

Поспелова Мария Львовна, д.м.н., ведущий научный сотрудник НИЛ неврологии и нейрореабилитации, доцент кафедры неврологии и психиатрии

Санкт-Петербург

Pospelova Maria L., MD, PhD, Leading Researcher of Neurology and Neurorehabilitation Scientific Research Department

Saint Petersburg

https://orcid.org/0000-0002-2115-8873ВасильеваЕ. Ю.VasilievaE. Yu.

Васильева Елена Юрьевна, заведующая Центральная клинико-диагностическая лаборатория, ассистент кафедры лабораторной медицины и генетики

Санкт-Петербург

Vasilieva Elena Yu., MD, Head of Central Clinical Diagnostics Laboratory, Assistant of the Department of Laboratory Medicine and Genetics

Saint Petersburg

СимаковК. В.SimakovK. V.

Симаков Каюм Владимирович, руководитель Регионального сосудистого центра, заведующий неврологическим отделением для лечения больных с острыми нарушениями мозгового кровообращения

Санкт-Петербург

Simakov Kayum V., MD, Head of the Regional Vascular Center, Head of the Neurological Department forthe Treatment of Patients with Acute Disorders of Cerebral Circulation

Saint Petersburg

https://orcid.org/0000-0003-2949-6268СергееваТ. В.SergeevaT. V.

Сергеева Татьяна Васильевна, к.м.н., заместитель главного врача по неврологии (руководитель Регионального сосудистого центра)

Санкт-Петербург

Sergeeva Tat’yana V., MD, PhD, Deputy Chief Physician for Neurology (Head of the Regional Vascular Center)

Saint Petersburg

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени B. A. Алмaзoвa» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CentreRussian FederationСанкт-Петербургское государственное бюджетное учреждение здравоохранения «Городская больница Cвятой преподобномученицы Елизаветы»РоссияHoly Martyr Elizabeth City HospitalRussian Federation202012102020752942Copyright © Алексеева Т.М., Топузова М.П., Чайковская А.Д., Панина Е.Б., Вавилова Т.В., Поспелова М.Л., Васильева Е.Ю., Симаков К.В., Сергеева Т.В., 20202020Алексеева Т.М., Топузова М.П., Чайковская А.Д., Панина Е.Б., Вавилова Т.В., Поспелова М.Л., Васильева Е.Ю., Симаков К.В., Сергеева Т.В.Alekseeva T.M., Topuzova M.P., Chaykovskaya A.D., Panina E.B., Vavilova T.V., Pospelova M.L., Vasilieva E.Y., Simakov K.V., Sergeeva T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/583биомаркеры инсультаглиальный фибриллярный кислый белокинсультишемический инсульткраткосрочный исходнейрон-специфическая енолазапрогноз NR2-антителаN-метил-D-аспартат рецепторыstrokestroke biomarkerneuron-specific enolaseglial fibrillary acidic proteinNR2-antibodiesN-methyl-D-aspartate receptorsshort-term outcomeprognosisReferencesFeigin VL, Norrving B, George MG, et al. Prevention of stroke: a strategic global imperative. Nat Rev Neurol. 2016; 12 (9): 501–512.Feigin VL, Norrving B, George MG, et al. Prevention of stroke: a strategic global imperative. Nat Rev Neurol. 2016; 12 (9): 501–512.Castellanos M, Serena J. Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis. 2007; 24 Suppl 1: 7–15.Castellanos M, Serena J. Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis. 2007; 24 Suppl 1: 7–15.Maas MB, Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med. 2009; 3 (4): 363–383.Maas MB, Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med. 2009; 3 (4): 363–383.Saengen AK, Christenson RH. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation and treatment. Clin Chem. 2010; 56 (1): 21–33.Saengen AK, Christenson RH. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation and treatment. Clin Chem. 2010; 56 (1): 21–33.Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3): 89–95.Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3): 89–95.Whiteley W, Tseng M-C, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke. 2008; 39(10): 2902–2909.Whiteley W, Tseng M-C, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke. 2008; 39(10): 2902–2909.Топузова М.П., Алексеева Т.М., Панина Е.Б. и др. Возможность использования нейрон-специфической енолазы как биомаркера в остром периоде инсульта. Журнал неврологии и психиатрии им. С. С. Корсакова. 2019; 119 (8-2): 53–62.Topuzova MP, Alekseeva TM, Panina EB, et al. The possibility of using neuron-specific enolase as a biomarker in the acute period of stroke. Zhurnal nevrologii i psihiatrii im. S. S. Korsakova=S.S. Korsakov journal of neurology and psychiatry. 2019; 119(8-2): 53–62. In RussianТопузова М.П., Алексеева Т.М., Панина Е.Б. и др. Возможность использования глиального фибриллярного кислого белка как биомаркера в остром периоде инсульта. Российский неврологический журнал. 2019; 24 (4): 4–15.Topuzova MP, Alekseeva TM, Panina EB, et al. The possibility of using glial fibrillary acidic protein as a biomarker in the acute period of stroke. Rossijskij nevrologicheskij zhurnal=Russian neurological journal. 2019; 24 (4): 4–15. In RussianТопузова М.П., Алексеева Т.М., Панина Е.Б. и др. NR2-антитела как диагностический и прогностический биомаркер при инсульте. Артериальная гипертензия. 2020; 26 (1): 27–36.Topuzova MP, Alekseeva TM, Panina EB, et al. NR2 antibodies as diagnostic and prognostic stroke biomarker. Arterial’naya gipertenziya=Arterial hypertension. 2020; 26 (1): 27–36. In RussianMissler U, Wiesmann M, Friedrich C, et al. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke. 1997; 28(10): 1956–1960.Missler U, Wiesmann M, Friedrich C, et al. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke. 1997; 28(10): 1956–1960.Laskowitz DT, Grocott H, Hsia A, et al. Serum markers of cerebral ischemia. J Stroke Cerebrovasc Dis. 1998; 7 (4): 234–241.Laskowitz DT, Grocott H, Hsia A, et al. Serum markers of cerebral ischemia. J Stroke Cerebrovasc Dis. 1998; 7 (4): 234–241.Eng LF. Glial fibrillary acidic protein (GFAP) the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol. 1985; 8 (4-6): 203–214.Eng LF. Glial fibrillary acidic protein (GFAP) the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol. 1985; 8 (4-6): 203–214.Missler U, Wiesmann M, Wittmann G, et al. Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem. 1999; 45 (1): 138–141.Missler U, Wiesmann M, Wittmann G, et al. Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem. 1999; 45 (1): 138–141.Lundgaard I, Osório MJ, Kress BT, et al. White matter astrocytes in health and disease. Neuroscience. 2014; 276: 161–173.Lundgaard I, Osório MJ, Kress BT, et al. White matter astrocytes in health and disease. Neuroscience. 2014; 276: 161–173.Kogure T, Kogure K. Molecular and biochemical events within the brain subjected to cerebral ischemia (targets for therapeutical intervention). Clin Neurosci. 1997; 4 (4): 179–183.Kogure T, Kogure K. Molecular and biochemical events within the brain subjected to cerebral ischemia (targets for therapeutical intervention). Clin Neurosci. 1997; 4 (4): 179–183.Shimada N, Graf R, Rosner G, et al. Ischemic flow threshold for extracellular glutamate increase in cat cortex. J Cereb Blood Flow Metab. 1989; 9 (5): 603–606.Shimada N, Graf R, Rosner G, et al. Ischemic flow threshold for extracellular glutamate increase in cat cortex. J Cereb Blood Flow Metab. 1989; 9 (5): 603–606.Jones TH, Morawetz RB, Crowell RM, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg. 1981; 54 (6): 773–782.Jones TH, Morawetz RB, Crowell RM, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg. 1981; 54 (6): 773–782.Choi DW, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci. 1987; 7 (2): 357–368.Choi DW, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci. 1987; 7 (2): 357–368.Benveniste H, Drejer J, Schousboe A, et al. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem. 1984; 43 (5): 1369–1374.Benveniste H, Drejer J, Schousboe A, et al. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem. 1984; 43 (5): 1369–1374.Meldrum B, Evans M, Griffiths T, et al. Ischaemic brain damage: the role of excitatory activity and of calcium entry. Br J Anaesth. 1985; 57 (1): 44–46.Meldrum B, Evans M, Griffiths T, et al. Ischaemic brain damage: the role of excitatory activity and of calcium entry. Br J Anaesth. 1985; 57 (1): 44–46.Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 1990; 13: 171–182.Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 1990; 13: 171–182.Okubo Y, Sekiya H, Namiki S, et al. Imaging extrasynaptic glutamate dynamics in the brain. Proc Natl Acad Sci USA. 2010; 107 (14): 6526–6531.Okubo Y, Sekiya H, Namiki S, et al. Imaging extrasynaptic glutamate dynamics in the brain. Proc Natl Acad Sci USA. 2010; 107 (14): 6526–6531.Wang Y, Qin Z-H. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis. 2010; 15 (11): 1382–1402.Wang Y, Qin Z-H. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis. 2010; 15 (11): 1382–1402.Li F, Tsien JZ. Memory and the NMDA receptors. N Engl J Med. 2009; 361 (3): 302–303.Li F, Tsien JZ. Memory and the NMDA receptors. N Engl J Med. 2009; 361 (3): 302–303.Levite M. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, antiNMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren’s syndrome, schizophrenia, mania or stroke. These autoimmune antiglutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor’s expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/ psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. J Neural Transm (Vienna). 2014; 121 (8): 1029–1075.Levite M. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, antiNMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren’s syndrome, schizophrenia, mania or stroke. These autoimmune antiglutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor’s expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/ psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. J Neural Transm (Vienna). 2014; 121 (8): 1029–1075.Gappoeva MU, Izykenova GA, Granstrem OK, et al. Expression of NMDA neuroreceptors in experimental ischemia. Biochemistry (Mosc). 2003; 68 (6): 696–702.Gappoeva MU, Izykenova GA, Granstrem OK, et al. Expression of NMDA neuroreceptors in experimental ischemia. Biochemistry (Mosc). 2003; 68 (6): 696–702.Gingrich MB, Traynelis SF. Serine proteases and brain damage – is there a link? Trends Neurosci. 2000; 23 (9): 399–407.Gingrich MB, Traynelis SF. Serine proteases and brain damage – is there a link? Trends Neurosci. 2000; 23 (9): 399–407.Dambinova SA, Khounteev GA, Skoromets AA. Multiple panel of biomarkers for TIA/stroke evaluation. Stroke. 2002; 33 (5): 1181–1182.Dambinova SA, Khounteev GA, Skoromets AA. Multiple panel of biomarkers for TIA/stroke evaluation. Stroke. 2002; 33 (5): 1181–1182.Дамбинова С.А., Скоромец А.А., Скоромец А.П. Биомаркеры церебральной ишемии. Разработка, исследование и практика. СПб.: ООО «ИПК Коста», 2013. 336 с..Dambinova SA, Skoromets AA, Skoromets AP. Biomarkers of cerebral ischemia. Development, research and practice. SPb.: “IPK Costa LLC”, 2013. 336 p. In RussianKlimenko LL, Skalny AV, Turna AA, et al. Serum trace element profiles, prolactin, and cortisol in transient ischemic attack patients. Biol Trace Elem Res. 2016; 172 (1): 93–100.Klimenko LL, Skalny AV, Turna AA, et al. Serum trace element profiles, prolactin, and cortisol in transient ischemic attack patients. Biol Trace Elem Res. 2016; 172 (1): 93–100.Nayak AR, Badar SR, Lande N, et al. Prediction of outcome in diabetic acute ischemic stroke patients: a hospital-based pilot study report. Ann Neurosci. 2016; 23 (4): 199–208.Nayak AR, Badar SR, Lande N, et al. Prediction of outcome in diabetic acute ischemic stroke patients: a hospital-based pilot study report. Ann Neurosci. 2016; 23 (4): 199–208.Kamchatnov PR, Chugunov AV, Ruleva NYu, et al. Autoantibodies to GFAP (glial fibrillary acidic protein) and to dopamine in patients with acute and chronic cerebrovascular disоrders. Health. 2010; 2 (12):1366–1371.Kamchatnov PR, Chugunov AV, Ruleva NYu, et al. Autoantibodies to GFAP (glial fibrillary acidic protein) and to dopamine in patients with acute and chronic cerebrovascular disоrders. Health. 2010; 2 (12):1366–1371.Ren C, Kobeissy F, Alawieh A, et al. Assessment of Serum UCH-L1 and GFAP in acute stroke patients. Sci Rep. 2016; 6: 24588.Ren C, Kobeissy F, Alawieh A, et al. Assessment of Serum UCH-L1 and GFAP in acute stroke patients. Sci Rep. 2016; 6: 24588.Weissman JD, Khunteev GA, Heath R, et al. NR2 antibodies: risk assessment of transient ischemic attack (TIA)/ stroke in patients with history of isolated and multiple cerebrovascular events. J Neurol Sci. 2011; 300 (1-2): 97–102.Weissman JD, Khunteev GA, Heath R, et al. NR2 antibodies: risk assessment of transient ischemic attack (TIA)/ stroke in patients with history of isolated and multiple cerebrovascular events. J Neurol Sci. 2011; 300 (1-2): 97–102.Дамбинова С.А., Алиев К.Т., Бондаренко Е.В. и др. Биомаркеры ишемии головного мозга как новый метод доказательства эффективности нейроцитопротекторов. Журнал неврологии и психиатрии им. C. C. Корсакова. 2017; 117 (5): 62–67.Dambinova SA, Aliev KT, Bondarenko EV, et al. The biomarkers of cerebral ischemia as a new method for the validation of the efficacy of cytoprotective therapy. Zhurnal nevrologii i psihiatrii im. S. S. Korsakova=S.S. Korsakov Journal of Neurology and Psychiatry. 2017; 117 (5): 62–67. In RussianUndén J, Strandberg K, Malm J, et al. Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation. J Neurol. 2009; 256 (1): 72–77.Undén J, Strandberg K, Malm J, et al. Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation. J Neurol. 2009; 256 (1): 72–77.Гусев Е.И., Скворцова В.И., Изыкенова Г.А. и др. Уровень аутоантител к глутаматным рецепторам в сыворотке крови у больных в остром периоде ишемического инсульта. Журнал неврологии и психиатрии им. C.C. Корсакова. 1996;96(5):68–72.Gusev EI, Skvortsova VI, Izykenova GA, et al. The level of autoantibodies to glutamate receptors in the blood serum of patients in the acute period of ischemic stroke. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 1996; 96 (5): 68–72. In RussianDambinova SA, Khounteev GA, Izykenova GA, et al. Blood test detecting autoantibodies to N-methyl-Daspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003; 49 (10): 1752–1762.Dambinova SA, Khounteev GA, Izykenova GA, et al. Blood test detecting autoantibodies to N-methyl-Daspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003; 49 (10): 1752–1762.Sienkiewicz-Jarosz H, Gałecka-Wolska M, Bidziński A, et al. Predictive value of selected biochemical markers of brain damage for functional outcome in ischaemic stroke patients. Neurol Neurochir Pol. 2009; 43 (2): 126–133.Sienkiewicz-Jarosz H, Gałecka-Wolska M, Bidziński A, et al. Predictive value of selected biochemical markers of brain damage for functional outcome in ischaemic stroke patients. Neurol Neurochir Pol. 2009; 43 (2): 126–133.Liu G, Geng J. Glial fibrillary acidic protein as a prognostic marker of acute ischemic stroke. Hum Exp Toxicol. 2018; 37 (10): 1048–1053.Liu G, Geng J. Glial fibrillary acidic protein as a prognostic marker of acute ischemic stroke. Hum Exp Toxicol. 2018; 37 (10): 1048–1053.

The authors declare that there are no conflicts of interest present.